A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX

NCT05467176 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

999

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Relugolix

Sponsor

Sumitomo Pharma America, Inc.